Warning: require_once(): It is not safe to rely on the system's timezone settings. You are *required* to use the date.timezone setting or the date_default_timezone_set() function. In case you used any of those methods and you are still getting this warning, you most likely misspelled the timezone identifier. We selected the timezone 'UTC' for now, but please set date.timezone to select your timezone. in /home/gkatak/public_html/HECOG-TRIALS/HE1000_TREATMENT/.excel/excel_reader2.php on line 916

Deprecated: Assigning the return value of new by reference is deprecated in /home/gkatak/public_html/HECOG-TRIALS/HE1000_TREATMENT/.excel/excel_reader2.php on line 916
  A B C D E F G
1 Clinical trial characteristics (HE10/00).            
2 Trial Accrual period N n Treatment schedule Eligibility criteria References
3 HE10/00

Australian New Zealand
Clinical Trials Registry
ACTRN12609001036202






































2000 - 2005








































1,086








































857








































E-T-CMF: Epirubicin 110 mg/m2 q 2 weeks x 3 followed by
paclitaxel 250 mg/m2 q 2 weeks x 3 followed by
cyclophosphamide 840 mg/m2, methotrexate 57 mg/m2,
fluorouracil 840 mg/m2 (CMF) q 2 weeks x 3. GCSF support
in all cycles.

ET-CMF: Epirubicin 83 mg/m2 + paclitaxel 187 mg/m2 q 3
weeks x 4 followed by cyclophosphamide 840 mg/m2,
methotrexate 57 mg/m2, fluorouracil 840 mg/m2 (CMF) q 2
weeks x 3. GCSF support in all cycles.

Patients with ER/PgR-positive tumors received tamoxifen 20
mg daily for five years. Premenopausal patients received
additional treatment with an LH-RH analog for two years.
Postmenopausal patients received tamoxifen 20 mg daily for
2-3 years followed 2-3 years of daily examestane 25 mg. All
patients who underwent partial mastectomy or with tumors
>5 cm and/or with e"4 infiltrated axillary nodes, irrespectively
of the type of surgery, were irradiated. Radiation therapy and
hormonal therapy were administered after the completion of
chemotherapy.











Eligible were women with:
histologically confirmed
epithelial breast cancer;
pathological stage T1-4 N1-2 M0;
Eastern Cooperative Oncology
Group performance status 0-1;
normal cardiac function; and
adequate bone marrow, hepatic
and renal function.























Fountzilas G, Dafni U, et al.
Postoperative dose-dense
sequential chemotherapy with
epirubicin, paclitaxel and CMF in
patients with high-risk breast cancer:
safety analysis of the Hellenic
Cooperative Oncology Group
randomized phase III trial HE
10/00. Ann Oncol. 2008;19:853-60.

Gogas H, Dafni U, et al.
Postoperative dose-dense
sequential versus concomitant
administration of epirubicin and
paclitaxel in patients with node-
positive breast cancer: 5-year
results of the Hellenic Cooperative
Oncology Group HE 10/00 phase
III Trial. Breast Cancer Res Treat.
2012;132(2):609-19.












4 N, number of patients enrolled in the trials; n, number of patients included in the current study with tumor tissue blocks available.